Targeting on the values of Wolbachia endosymbionts as novel feasible anti-filarial chemotherapeutic approach to prevent/reduce/clear disease in lymphatic filariasis and interrupt transmission in endemic communities of Tanzania
ISRCTN | ISRCTN12273637 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN12273637 |
Secondary identifying numbers | N/A |
- Submission date
- 26/01/2009
- Registration date
- 05/03/2009
- Last edited
- 05/03/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Achim Hoerauf
Scientific
Scientific
Director, MD
Institute of Medical Microbiology, Immunology and Parasitology
University of Bonn, Faculty of Medicine
Sigmund Freud Str. 25
Bonn
53105
Germany
Phone | +49 (0)228 287 15675 |
---|---|
hoerauf@microbiology-bonn.de |
Study information
Study design | Randomised double-blind placebo-controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Other |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Targeting on the values of Wolbachia endosymbionts as novel feasible anti-filarial chemotherapeutic approach to prevent/reduce/clear disease in lymphatic filariasis and interrupt transmission in endemic communities of Tanzania: a randomised double-blind placebo-controlled trial |
Study objectives | Wolbachia endosymbionts bacteria are associated with inflammatory process in their human-host and filarial nematode causing overt clinical disease. However, the use of antibiotics with macrofilaricidal activity (doxycycline) that kills adult worms, might prevent or halt/cure/clear clinical disease such as lymphoedema (LE), acute dermatoadenolymphangitis (ADLA) or acute filarial fevers with lymphangitis (AFL). In the present study, it will be investigated whether patients with ongoing infection (i.e., who are positive for circulating filarial antigen [CFA]) will benefit more, in the same way or less than patients without ongoing infection (i.e. CFA negative) but remaining pathology. |
Ethics approval(s) | The Medical Research Coordinating Committee of Tanzania approved on 11th November 2005 (ref: NIMR/HQ/R.8a/vol.IX/403) |
Health condition(s) or problem(s) studied | Wuchereria bancrofti lymphoedema stage I - V |
Intervention | 45 individuals with circulating filarial antigen positive (CFA) and 45 individuals without circulating filarial antigen in their blood will be randomised to: 1. 200 mg/day doxycycline for 6 weeks 2. Placebo for 6 weeks Contact details for co-investigator: Dr WH Makunde National Institute for Medical Research Tanga Centre P.O. Box 5004 Tanga Tanzania Tel: +255 27 26 46084 Fax: +255 27 26 43869 E-mail hwmakunde@hotmail.com |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase II |
Drug / device / biological / vaccine name(s) | Doxycycline |
Primary outcome measure | 1. Proportion of patients whose lymphoedema is reduced in size or cured 2. Proportion of acute filarial fevers and acute dermatoadenolymphangitis episodes or subclinical episodes prevented or reduced or halted during the trial period 3. Levels of CFA reduced or cleared 4. Levels of vascular endothelial growth factors (VEGFs) and pro-inflammatory immunological responses in plasma pre-post treatment in different stages of LE individuals |
Secondary outcome measures | 1. The length of time taken for LE to change in size or cured or reappear again 2. The levels of anti-Wolbachia surface protein antibodies response at pre-post treatment 3. Tolerability of the anti-Wolbachia agent (antibiotic-doxycycline) (drug adverse events) |
Overall study start date | 27/09/2008 |
Completion date | 21/11/2010 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 90 individuals with lymphoedema |
Key inclusion criteria | 1. Age range 18 - 68 years 2. Males and females 3. Diagnosed clinically to have lymphoedema stages I - V 4. Permanent residents in the study area 5. May be microfilaraemia positive or negative |
Key exclusion criteria | 1. Children and pregnant women 2. Chronic liver, kidney, cardiac, central nervous system disease 3. Allergy to the trial drugs 4. Previous history of using anti-filarial drugs, e.g. ivermectin, albendazole, diethylcarbamazine 5. Past history of taking anti-geohelminthics, e.g. mebendazole, and antibiotics such as tetracycline or rifampicin in the last six months |
Date of first enrolment | 27/09/2008 |
Date of final enrolment | 21/11/2010 |
Locations
Countries of recruitment
- Germany
- Tanzania
Study participating centre
Director, MD
Bonn
53105
Germany
53105
Germany
Sponsor information
Volkswagen Foundation (VolkswagenStiftung) (Germany)
Research organisation
Research organisation
c/o Dr. Detlev Hanne
Division Natural and Engineering Sciences, Medicine
Kastanienallee 35
Hannover
30519
Germany
Phone | +49 (0)511 8381 0 |
---|---|
info@volkswagenstiftung.de | |
Website | http://www.volkswagenstiftung.de |
https://ror.org/03bsmfz84 |
Funders
Funder type
Research organisation
Volkswagen Foundation (VolkswagenStiftung) (Germany)
Private sector organisation / Trusts, charities, foundations (both public and private)
Private sector organisation / Trusts, charities, foundations (both public and private)
- Alternative name(s)
- VolkswagenStiftung
- Location
- Germany
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |